Advanced, metastatic or recurrent olaparib |
Low |
February 2023 |
Breast metastatic abemaciclib3 |
Low |
February 2023 |
Breast metastatic AC (DOXOrubicin and CYCLOPHOSPHamide) |
Medium |
February 2025 |
Breast metastatic anastrozole |
Low |
February 2025 |
Breast metastatic capecitabine |
Low |
February 2024 |
Breast metastatic capecitabine and lapatinib |
Low |
February 2026 |
Breast metastatic capecitabine and trastuzumab |
Low |
February 2024 |
Breast metastatic cARBOplatin and Gemcitabine |
Medium, Day 1. Low, Day 8 |
February 2026 |
Breast metastatic denosumab |
Low |
February 2024 |
Breast metastatic DOCEtaxel and trastuzumab three weekly |
Medium. Moves to low risk after completion of DOCEtaxel treatment) |
February 2025 |
Breast metastatic DOCEtaxel three weekly |
Medium |
February 2025 |
Breast metastatic DOCEtaxel, pertuzumab and trastuzumab |
Medium. Moves to low risk after completion of DOCEtaxel treatment) |
February 2025 |
Breast metastatic DOXOrubicin three weekly |
Medium |
February 2025 |
Breast metastatic DOXOrubicin weekly |
Medium |
February 2025 |
Breast metastatic epirubicin weekly - Approved SAHCDC Breast metastatic epirubicin weekly protocol (PDF 1737KB) |
Medium |
December 2021 |
Breast metastatic EC (epirubicin and CYCLOPHOSPHamide) |
Medium |
February 2025 |
Breast metastatic eribulin |
Medium |
February 2025 |
Breast metastatic everolimus and exemestane |
Low |
February 2024 |
Breast metastatic exemestane |
Low |
February 2022 |
Breast metastatic fulvestrant3 |
Low |
February 2024 |
Breast metastatic goserelin |
Low |
February 2025 |
Breast metastatic letrozole |
Low |
February 2025 |
Breast metastatic nab-PACLItaxel weekly |
Medium |
February 2025 |
Breast metastatic PACLItaxel weekly |
Medium |
February 2025 |
Breast metastatic PACLItaxel weekly and trastuzumab three weekly |
Medium. Moves to low risk after completion of PACLitaxel treatment) |
February 2025 |
Breast metastatic PACLItaxel weekly, pertuzumab and trastuzumab three weekly |
Medium4 |
February 2024 |
Breast metastatic palbociclib |
Low |
February 2024 |
Breast metastatic pegylated liposomal DOXOrubicin |
Medium |
February 2025 |
Breast metastatic ribociclib |
Low |
February 2024 |
Breast metastatic sacituzumab govitecan |
Medium3 |
August 2023 |
Breast metastatic tamoxifen |
Low |
February 2025 |
Breast metastatic trastuzumab emtansine |
Medium1 |
February 2024 |
Breast metastatic trastuzumab three weekly |
Low |
February 2025 |
Breast metastatic trastuzumab three weekly and vinORELBine (IV) |
Medium. Moves to low risk after completion of vinORELbine treatment) |
February 2026 |
Breast metastatic trastuzumab three weekly and vinORELBine (oral) |
Low |
February 2025 |
Breast metastatic vinORELBine (IV) |
Medium |
February 2025 |
Breast metastatic vinORELBine (oral) |
Low |
February 2025 |
Breast metastatic zoledronic acid |
Low |
February 2024 |